Hubei Tianji Pharmaceutical Co., Ltd. announced that it will receive CNY 60 million in an equity round of funding from new investor Tibet Duo Rui Pharmaceutical Co.,Ltd. to acquire 5.66% stake in the company on November 14, 2022. The CNY 18 million will go to the registered capital and the CNY 42 million will go to capital reverse. After the completion of transaction, registered capital will change from CNY 300 million to CNY 318 million.

The transaction has been approved at eighteenth meeting of the first board of directors and the sixteenth meeting of the first board of supervisors.